Novartis: The Profit Upgrade Is Real, the Sales Guide Is Not
The Beat Is a Margin Story
Novartis did not raise its sales outlook for 2026. It raised the profit line. Q3 net sales rose 4% in constant currency to $14.5 billion, while core operating income rose 10% to $6 billion and the core margin reached 41.6%, up two percentage points. That combination — modest revenue growth, double-digit profit growth — is the whole quarter in one sentence. CFO Mukul Mehta was explicit: “we are raising our full-year ... guidance for core operating income. We now expect for the full year 2026, core operating income to be in line to growing low single digit.” — Mukul Mehta, Chief Financial Officer · 2026-10-27 The top-line guide remained low single digit.
The engine was not price or volume leverage; it was the SG&A line. SG&A fell 7% year over year even as sales grew 4%. Mehta framed this as durable productivity, pointing to roughly $11 billion of annual third-party spend in categories like agency, travel, consulting and professional services, where technology and AI are helping Novartis capture its “fair share” of efficiency. That is a new rationale on this call — a more explicit AI-cost lever than the generic “productivity programs” language of prior quarters. But it is not a new theme. A year ago, the same finance organization said the gross-margin headwinds would be offset by margin improvement from SG&A productivity: “the gross margin headwinds, I do expect to be offset by SG&A productivity.” — Harry Kirsch, Chief Financial Officer · 2025-10-28 And in February, Mehta’s predecessor was already praising SG&A cost control built over “the last 4, 5 years.” The Q3 number is excellent; the surprise is its magnitude, not its existence.
Mehta also threw cold water on extrapolation: “taking 1 quarter and saying that is the estimate now for the next 3 years, I think is extrapolating it for the full year is not the right thing.” — Mukul Mehta, Chief Financial Officer · 2026-10-27 Q4 will carry the usual year-end spend, higher royalties as growth drivers scale, and lower other income from Xolair biosimilars. The margin guide is still 40%-plus by 2029, not 40%-plus forever starting now.
Replacement Power, With a Smaller Net
The growth drivers did their job. Kisqali grew 37%, Kesimpta 22%, Pluvicto 20%, Leqvio 63%, Scemblix 67%, and Cosentyx 9%. Priority brands collectively rose 29%. That is genuine replacement power against Entresto, Tasigna and Promacta/Revolade generic erosion in the U.S. CEO Vasant Narasimhan called it out directly:
But the net result was still 4% total growth. The new products are not yet large enough to more than offset the old ones, which is why the full-year sales guide did not move.The really shows the replacement power of the business. We have been able to successfully navigate the Entresto, Tasigna, Promacta/Revolade in the US, demonstrating we grew through the year.
Leqvio remains the cleanest growth story, with the Orion 4 cardiovascular-outcomes readout expected around year-end and VICTORION-2P in 2027. Management expects both to read out positively given Leqvio’s LDL lowering, but the CEO conceded Orion 4 was partly run during the pandemic. That is a soft caveat worth remembering. Pluvicto’s PSMA addition launch is also slower than the headline: the CEO described a 5-to-10-week lead time for new patients and said Q4 will see “some uptake” before a stronger 2027. This is consistent with the S-shaped launch language from last year, not a new miss.
Peak Sales vs. Near-Term Reality
The quarterly keyword board tells the story: Peak sales sits at the top of Novartis’s own theme list. Management leaned hard on peak-sales promises to bridge the gap between today’s low-single-digit sales guide and the long-term growth algorithm. Remibrutinib in RMS and CSU/CIndU is now framed as an $8 billion-plus opportunity: “clear $4 billion for CSU and CIndU, $4 billion for the current MS readout ... equals $8 billion-plus.” — Vasant Narasimhan, Chief Executive Officer · 2026-10-27 Rhapsido’s peak sales guidance was raised to more than $4 billion across CSU and CIndU. Those are big numbers — and they are exactly what a company reaches for when the near-term top line is constrained.
The contrast with February is stark. Back then, Narasimhan’s base case was cautious on oral BTK in MS: “our base case assumption is that an oral drug will struggle to have the same level of efficacy as monoclonal antibodies in hitting the B-cell pathways in MS.” — Vasant Narasimhan, Chief Executive Officer · 2026-02-04 Now, after the RMS readout, remibrutinib is being positioned as a disease control story with a clean safety profile and a large switch opportunity. The data may justify the shift. But investors should note that the $4 billion MS number rests on a thesis management was explicitly hedging against six months ago.
The pipeline bill also came due. Delgociptacine missed the HARBOR primary endpoint in DMD, triggering a $1.9 billion partial impairment and pushing the timeline out. Pelacarsen’s HORIZON study missed its primary endpoint. Those are two expensive reminders that peak-sales math is optionality, not cash flow. The wins — remibrutinib, Rhapsido, Pluvicto label expansion — are real, but they are carrying more of the narrative now because the failures removed some of the cushion.
The Cracks Management Is Naming
The most interesting admissions were competitive, not financial. On renal, Narasimhan conceded that anti APRILs have reset the IgAN landscape: “the anti-APRILs have changed the landscape ... they are the standard of care ... we have had to think carefully now on how to position these medicines.” — Vasant Narasimhan, Chief Executive Officer · 2026-10-27 Novartis has its own anti-APRIL asset, but management expects to be third to market. That turns Fabhalta and Vanrafia from “stacked blockbusters” into products that must be geographically tailored and repositioned. It is a candid admission that one of the company’s key renal growth pillars is in “a state of flux.”
Then there is Xolair biosimilar pressure. The CFO quantified the coming drag at roughly 2 to 2.5 percentage points of margin erosion as U.S. Xolair biosimilars bite:
That is a concrete, multi-year headwind sitting underneath the upbeat Q3 margin print. It does not invalidate the 40%-by-2029 target, but it explains why management will not call 41.6% the new base.we would see pressure on the margin over the next couple of years as a result of Xolair biosimilars in the US.
Pluvicto is the other watch item. The PSMA addition launch is strategically important because it is supposed to take Pluvicto toward the $5 billion peak. The CEO’s language was careful: “we do expect there to be steady uptake ... this is going to take time to develop.” — Vasant Narasimhan, Chief Executive Officer · 2026-10-27 After a flat U.S. sales pattern in recent quarters, the market will want to see Q4 and Q1 scripts confirm that mHSPC is inflecting, not just that the label exists.
What to Watch
This was a high-quality margin beat wrapped in a cautious top-line guide. The profit upgrade is real, but it is cost-led and partly one-quarter in nature. The sales guide is unchanged because generic erosion is still outrunning the growth drivers. The pipeline is a mixed ledger: remibrutinib and Rhapsido are now credible multi-billion-dollar assets, while delgociptacine and pelacarsen have moved from catalysts to sunk costs. The stock story from here hinges on three things: whether SG&A productivity persists into 2027, whether Xolair biosimilar erosion lands at the low or high end of the 2-to-2.5-point range, and whether Pluvicto’s mHSPC launch turns into a real curve rather than a slow grind. Novartis has earned the benefit of the doubt on cost. It has not yet earned it on the top line.